VOICED : Falla un medicamento de Novartis contra el covid-19

Novartis announced that their clinical trials for Ruxolitinib, aimed at treating severe COVID-19 cases, did not yield the expected results in reducing hospitalizations. The Phase 3 trial showed no significant improvement, but this does not affect ongoing research for other diseases. Ruxolitinib is already marketed under the name Havaki for other uses. Novartis plans to continue working with the medical community to analyze these results and gain a better understanding of COVID-19. For more details, visit www.alimmenta.com.

What new insight or understanding did you gain from this video?